Inaktiver Wert

Andere Sprachen BioLight Life Sciences Ltd. TEL AVIV STOCK EXCHANGE

Aktien

BioLight Life Sciences : Calling of Special Meeting for May 9, 2024 - Company announcement	01.04.
BioLight Life Sciences Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	21.03.
BioLight Life Sciences : Calling of Annual Meeting for April 8, 2024 - Company announcment	04.03.
BioLight Life Sciences Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	31.08.23
Diagnostear, a subsidiary of BioLight Life Sciences Ltd, signed a binding Letter of Intent for merger, capital raise and listing on the Canadian Securities Exchange	12.06.23
BioLight Life Sciences Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	31.05.23
BioLight Life Sciences Announces Results from its Glaucoma Insert VS101 Phase 1/2A Clinical Trial	24.07.17
DiagnosTear Ltd. to Provide Analysis Services Through its TeaRx Multi-Parameter Diagnostic Assays for Use in an Clinical Trial for Dry Eye Syndrome	23.02.17
A Chinese investor signed Memorandum of Understanding to acquire 45% stake in BioLight Life Sciences Ltd. from public for ILS 19.4 million.	29.12.16
BioLight Reports Feasibility Clinical Study Results for the Detection of Prostate Cancer with CellDetect® Non-Invasive Test	26.07.16
BioLight Life Sciences Ltd. Receives worldwide rights for Eye Drops for Dry Eye Syndrome	19.05.16

Keine Ergebnisse zu dieser Suche